$10.09 Million in Sales Expected for Nurix Therapeutics, Inc. (NASDAQ:NRIX) This Quarter

Brokerages expect Nurix Therapeutics, Inc. (NASDAQ:NRIXGet Rating) to report sales of $10.09 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Nurix Therapeutics’ earnings, with estimates ranging from $8.00 million to $11.54 million. Nurix Therapeutics posted sales of $7.09 million during the same quarter last year, which indicates a positive year-over-year growth rate of 42.3%. The business is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Nurix Therapeutics will report full year sales of $50.48 million for the current year, with estimates ranging from $33.62 million to $72.16 million. For the next financial year, analysts expect that the company will post sales of $73.56 million, with estimates ranging from $43.20 million to $108.12 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Nurix Therapeutics.

Nurix Therapeutics (NASDAQ:NRIXGet Rating) last announced its quarterly earnings data on Thursday, April 7th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.06). Nurix Therapeutics had a negative net margin of 394.21% and a negative return on equity of 38.11%. The firm had revenue of $9.62 million for the quarter, compared to analysts’ expectations of $8.77 million.

NRIX has been the topic of several recent research reports. Zacks Investment Research raised Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 9th. Wells Fargo & Company decreased their price objective on Nurix Therapeutics from $28.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, April 11th. HC Wainwright cut their price objective on Nurix Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, April 14th. Royal Bank of Canada dropped their target price on Nurix Therapeutics from $42.00 to $39.00 and set an “outperform” rating on the stock in a report on Monday, April 18th. Finally, Robert W. Baird decreased their price objective on shares of Nurix Therapeutics from $49.00 to $41.00 in a research note on Friday, January 28th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $46.17.

NASDAQ NRIX opened at $9.98 on Monday. The business has a 50-day moving average price of $12.50 and a 200-day moving average price of $19.87. Nurix Therapeutics has a twelve month low of $8.40 and a twelve month high of $37.42. The firm has a market cap of $448.60 million, a price-to-earnings ratio of -3.27 and a beta of 2.59.

Several large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Nurix Therapeutics by 307.2% during the 1st quarter. The Manufacturers Life Insurance Company now owns 66,700 shares of the company’s stock worth $943,000 after buying an additional 50,318 shares during the period. Nomura Holdings Inc. raised its holdings in Nurix Therapeutics by 72.8% during the 1st quarter. Nomura Holdings Inc. now owns 305,340 shares of the company’s stock worth $4,265,000 after buying an additional 128,674 shares during the period. Alyeska Investment Group L.P. raised its holdings in Nurix Therapeutics by 5.0% during the 1st quarter. Alyeska Investment Group L.P. now owns 120,750 shares of the company’s stock worth $1,692,000 after buying an additional 5,750 shares during the period. Quantbot Technologies LP raised its holdings in shares of Nurix Therapeutics by 211.1% in the first quarter. Quantbot Technologies LP now owns 5,600 shares of the company’s stock valued at $78,000 after purchasing an additional 3,800 shares during the last quarter. Finally, Ensign Peak Advisors Inc boosted its position in Nurix Therapeutics by 1,634.1% during the first quarter. Ensign Peak Advisors Inc now owns 84,797 shares of the company’s stock worth $1,188,000 after purchasing an additional 79,907 shares during the period. 89.94% of the stock is owned by institutional investors.

Nurix Therapeutics Company Profile (Get Rating)

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

See Also

Get a free copy of the Zacks research report on Nurix Therapeutics (NRIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.